Related Experiment Videos
Complement activation in Brazilian patients with preeclampsia
I J de Messias-Reason1, V Aleixo, H de Freitas
1Immunopathology Laboratory, Department of Medical Pathology, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba-Pr, Brazil. Immunopat@hc.uppr.br
Journal of Investigational Allergology & Clinical Immunology
|October 20, 2000
Summary
Complement activation, indicated by elevated SC5b-9 and C3d levels, is confirmed in preeclampsia patients. These markers decreased post-delivery, suggesting complement
Area of Science:
- Obstetrics and Gynecology
- Immunology
- Pathophysiology
Background:
- Preeclampsia is a serious pregnancy complication.
- The role of the complement system in preeclampsia pathogenesis requires further elucidation.
Purpose of the Study:
- To investigate complement activation in Brazilian preeclampsia patients.
- To correlate complement activation markers with disease severity and clinical outcomes.
Main Methods:
- Plasma levels of C3d, SC5b-9, C3, and C4 were measured in preeclamptic and normotensive pregnant women.
- Assays included turbidimetry, rocket immunoelectrophoresis, and ELISA.
- Complement markers were assessed before and after delivery.
Main Results:
- Significantly higher levels of C3d, SC5b-9, C3, and C4 were observed in preeclamptic patients compared to controls.
- The terminal complement complex SC5b-9 and C3d showed the most significant elevations.
- All measured complement markers decreased significantly after delivery.
- No significant differences in complement markers were found concerning preeclampsia severity.
Conclusions:
- Complement activation is confirmed in preeclampsia.
- Complement activation is linked to the manifestation of preeclampsia.
- The study highlights the involvement of complement in preeclampsia's pathology.